Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 210 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PRE- MISTIC: MRI and Cine Imaging to Improve Staging of Tumors in the Colon
Node-sparing Modified Short-Course Radiation Combined With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer : A Randomized, Prospective, Multicenter, Open-label Clinical Trial
HDAC Inhibitor Combination With Immunochemotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: A Multicenter, Double-arm, Phase II Randomized Controlled Study
Assessment of Long-Term Chemotherapy-Induced Peripheral Neuropathy and Its Impact on Quality of Life in Colon Cancer Patients After Neoadjuvant Platinum-Containing Chemotherapy
Phase II Trial of Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Machine Learning-Based Exosomal microRNA Signature for Preoperative Staging and Chemotherapy Eligibility in Colon Cancer
Who cites it
210 citing papers in PubMed, 10 syntheses or guidelines pooled it, 408 citations in OpenAlex.
- Tumor characteristics impact prognosis in deficient mismatch repair/microsatellite instability-high localized colorectal cancer-a systematic review and meta-analysis.JNCI cancer spectrum · 2026Pooled it
- CT diagnostic performance for preoperative staging of colon cancer: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Diagnostic accuracy of CT for identifying high-risk colon cancer: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Clinical Practice Guideline: Colorectal Cancer—Diagnosis, Treatment, Prevention, and Long-Term Follow-Up Care.Deutsches Arzteblatt international · 2025Guideline
- The reporting of health systems data use in primary results publications of clinical trials: a systematic review.Trials · 2025Pooled it
- Treatment with curative intent for locoregional recurrent colon cancer - a systematic review.BMC surgery · 2025Pooled it
- Risk of peritoneal metastasis following minimally invasive colectomy for locally advanced colon cancer: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment.Annals of coloproctology · 2024Guideline
- Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis.The British journal of surgery · 2024Pooled it
- Factors associated with changes in the quality of postoperative recovery after laparoscopic colorectal cancer surgery in women: a linear mixed-effects analysis.Journal of anesthesia · 2026Trial
- Trial
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.The New England journal of medicine · 2026Trial
- Trial
- CT-based radiogenomic analysis to predict high-risk colon cancer (ATTRACT): a multicentric trial.European radiology · 2025Trial
- CT staging performance in an international trial of neoadjuvant chemotherapy for locally advanced colon cancer.The British journal of radiology · 2025Trial
- Development of the rationale of a personalized cancer vaccine based on the in situ vaccine effect of radiotherapy: a mechanistic study of the POLARSTAR trial.Cancer immunology, immunotherapy : CII · 2025Trial
- Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.ESMO open · 2025Trial
- Underdiagnosis of positive resection margins and synchronous peritoneal metastases in locally advanced colon cancer: histopathological reassessment of primary resection in the COLOPEC trial.Virchows Archiv : an international journal of pathology · 2025Trial
- Toripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial.Cell reports. Medicine · 2025Trial
150 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
Abstract
purposeNeoadjuvant chemotherapy (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon cancer but requires formal evaluation.
methodsPatients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly allocated (2:1) to 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 postoperatively (NAC group) or 24 weeks postoperatively (control group). Patients with
resultsOf 699 patients allocated to NAC, 674 (96%) started and 606 (87%) completed NAC. In total, 686 of 699 (98.1%) NAC patients and 351 of 354 (99.2%) control patients underwent surgery. Thirty patients (4.3%) allocated to NAC developed obstructive symptoms requiring expedited surgery, but there were fewer serious postoperative complications with NAC than with control. NAC produced marked T and N downstaging and histologic tumor regression (all
conclusionSix weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy for operable colon cancer can be delivered safely, without increasing perioperative morbidity. This chemotherapy regimen, when given preoperatively, produces marked histopathologic down-staging, fewer incomplete resections, and better 2-year disease control. Histologic regression after NAC is a strong predictor of lower postoperative recurrence risk so has potential use as a guide for postoperative therapy. Six weeks of NAC should be considered as a treatment option for locally advanced colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.